ReviewFrontiers in immunology2026
Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by releasing inhibitory pathways that restrain antitumor T-cell responses. Their success has renewed interest in checkpoint blockade for infectious diseases, particularly chronic viral infections, sepsis-associated immunosuppression, and refractory opportunistic infections. In these settings, immune checkpoints may contribute to pathogen persistence by limiting effector function, but they also restrain tissue injury, cytokine excess, and immune-mediated organ damage. This dual role makes translation fundamentally different from oncology: the goal is not maximal immune activation, but controlled immune recalibration. Evidence is strongest for chronic viral infections and selected oncology-adjacent cohorts, whereas infection-directed trials remain early and heterogeneous. A precision framework based on pathogen burden, immune phenotype, tissue vulnerability, biomarker feasibility, safety monitoring, and implementation context is therefore essential before ICIs can be responsibly developed as host-directed therapies for infectious diseases. This review synthesizes the rationale, evidence, and safety considerations for ICIs in infectious diseases. We discuss chronic viral infections, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Epstein-Barr virus (EBV), and highlight EBV as a bridge between persistent viral infection, immune surveillance, lymphoproliferation, and cancer immunotherapy. We also examine tuberculosis, sepsis, fungal infections, and parasitic diseases, where checkpoint pathways may restore host defense or amplify immunopathology. Finally, we propose a precision-immunotherapy framework integrating pathogen biology, immune phenotype, tissue risk, biomarker feasibility, access, and trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.